A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations

Tuesday, July 26, 2022

Dr. Minal Barve

Read the Story Here

Related Publications

Discover more publications from our trials.

A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma

Sep 5, 2024

ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab- Paclitaxel in Patients with Advanced Solid Tumors

Sep 5, 2024

Preliminary Clinical Activity of RMC-6236, a First-in-Class, RAS-Selective, Tri-Complex RASMULTI(ON) Inhibitor in Patients with KRAS-Mutant Pancreatic Ductal Adenocarcinoma (PDAC) and Non-Small Cell Lung Cancer (NSCLC)

Aug 23, 2024

Dr. Minal Barve
See All Posts